A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Clinical trial NCT02623972 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02623972
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Inflammatory Breast Cancer Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Start date: 2016-02-26
Primary completion: 2021-05-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.